Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Mar 4, 2026, 08:40Wolfgang Miesbach։ Highlighting the Social and Psychological Impact of Factor VII Deficiency
-
Mar 3, 2026, 17:12Matteo Foschi: Cancer Worsens Prognosis after Breakthrough Ischemic Stroke Despite Oral Anticoagulation
-
Mar 3, 2026, 17:04Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
-
Mar 3, 2026, 16:58Non-Carrier Mothers of Inv22 Hemophilia A Patients Frequently Harbor Additional F8 Gene Rearrangements – JTH
-
Mar 3, 2026, 16:53Valentina Rossi: Addressing Inflammation and Immune Mechanisms in Cardiomyopathy Management
-
Mar 3, 2026, 16:45Emmanuel J Favaloro: New Publication on Artificial Intelligence in Thrombosis and Hemostasis in CCLM
-
Mar 3, 2026, 16:32Scott E. Smith: Why Hematology Research Is the True Leader of all Medical Disciplines
-
Mar 3, 2026, 16:21Tareq Abadl: Why HIV Antibodies Stay Positive Even When Viral Load Is Zero?
-
Mar 3, 2026, 16:12Mark Crowther Congratulates Mary Cushman on Her Appointment as ISTH President